Erasca (ERAS) EBITDA (2020 - 2026)
Erasca's (ERAS) quarterly EBITDA came in at -$187.9 million in Q1 2026, down 427.4% YoY from $57.4 million in Q1 2025, and down 476.34% on a QoQ basis from -$32.6 million in Q4 2025.
Erasca (ERAS) EBITDA (2020 - 2026) Analysis & Trends
Erasca (ERAS) has 7 years of EBITDA data on file, last reported at -$187.9 million in Q1 2026.
- Quarterly EBITDA fell 427.4% year-over-year to -$187.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$293.2 million (down 66.24% YoY) and the FY2025 annual result came in at -$140.9 million, up 21.54% from the prior year.
- EBITDA slipped to -$187.9 million in Q1 2026, from -$32.6 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$32.6 million in Q4 2025 to a low of -$187.9 million in Q1 2026.
- A 5-year average of -$52.8 million and a median of -$36.5 million in 2022 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2023 — EBITDA jumped 75.47% — and 2026, when it plunged 427.4%.
- Tracing ERAS's EBITDA over 5 years: stood at -$138.1 million in 2022, then jumped by 75.47% to -$33.9 million in 2023, then fell by 5.43% to -$35.7 million in 2024, then increased by 8.7% to -$32.6 million in 2025, then plunged by 476.34% to -$187.9 million in 2026.
- The last three EBITDA figures came in at -$187.9 million (Q1 2026), -$32.6 million (Q4 2025), and -$34.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Erasca | 6.43 Bn | 6.16 Bn | - | -47.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -47.62 Mn |
| Mar 31, 2026 | -187.91 Mn |
| Dec 31, 2025 | -32.60 Mn |
| Sep 30, 2025 | -34.55 Mn |
| Jun 30, 2025 | -38.13 Mn |
| Mar 31, 2025 | -35.63 Mn |
| Dec 31, 2024 | -35.71 Mn |
| Sep 30, 2024 | -37.24 Mn |
| Jun 30, 2024 | -67.78 Mn |
| Mar 31, 2024 | -38.85 Mn |
| Dec 31, 2023 | -33.87 Mn |
| Sep 30, 2023 | -34.66 Mn |
| Jun 30, 2023 | -35.97 Mn |
| Mar 31, 2023 | -37.03 Mn |
| Dec 31, 2022 | -138.08 Mn |
| Sep 30, 2022 | -36.96 Mn |
| Jun 30, 2022 | -35.91 Mn |
| Mar 31, 2022 | -36.51 Mn |
| Dec 31, 2021 | -31.05 Mn |
| Sep 30, 2021 | -46.04 Mn |